𝗖𝗥𝗜𝗦𝗣𝗥𝗠𝗘𝗗𝟮𝟱: 𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝘀𝗶𝘅 𝗱𝗶𝘀𝘁𝗶𝗻𝗴𝘂𝗶𝘀𝗵𝗲𝗱 𝘀𝗽𝗲𝗮𝗸𝗲𝗿𝘀!
Eric B. Kmiec, Founder and Executive Director of ChristianaCare Gene Editing Institute, specialises in advancing CRISPR-based therapies for solid tumours. By applying a translational and educational approach, he and his team aim to enable breakthrough technologies to reach underserved populations. In addition, he has founded biotech companies including Kimeragen (now Cibus) and CorriXR Therapeutics, where he serves as Chief Executive Officer and Chief Scientific Officer.
Raffaella Di Micco, Group Leader at San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Milan and Associate Professor of Pathology at Istituto Universitario di Studi Superiori, Pavia, Pavia, focuses her research on optimising gene therapies for genetic disorders based on haematopoietic stem and progenitor cells. Her expertise spans cellular aging and differentiation, and cancer biology.
Matthew Porteus, Sutardja Chuk Professor of Definitive and Curative Medicine at Stanford University School of Medicine, leads the Stanford Center for Definitive and Curative Medicine and co-directs the Cell and Gene Therapy GMP Facility. As an attending physician at Lucile Packard Children’s Hospital, he specialises in stem cell transplants for both malignant and non-malignant conditions.
Thorsten Stafforst, Professor of Nucleic Acid Biochemistry at the Interfaculty Institute of Biochemistry at the Eberhard Karls Universität Tübingen, centres his research on RNA-based drug development and RNA-guided technologies. As a co-founder of the Gene and RNA Therapy Centre and AIRNA Bio, he applies his chemistry and bioengineering expertise to advance therapeutic RNA engineering.
Julian Grünewald, Physician-scientist at the Technische Universität München, leads a team developing innovative CRISPR technologies for research and therapeutic applications in cardiovascular medicine. After training as a resident of internal medicine, he conducted postdoctoral research in the laboratory of J. Keith Joung at Massachusetts General Hospital and Harvard Medical School.
Rob Wolthuis, Associate Professor and Head of the Oncogenetics Section at Amsterdam UMC, leads genome-wide screening projects to uncover the genetic underpinnings of drug responses and mechanisms of drug resistance. His team’s work includes developing CRISPR-based applications, such as using Cas12 for genome diagnostics, aiming for clinical integration of targeted gene editing.
See our 𝗳𝘂𝗹𝗹 𝗶𝗻𝘃𝗶𝘁𝗲𝗱 𝘀𝗽𝗲𝗮𝗸𝗲𝗿 𝗹𝗶𝘀𝘁 here:
👉 https://lnkd.in/d7svujCE
We are looking forward to your registration!
👉 https://lnkd.in/d2wyXiAH
#CRISPRMED25 #crisprmedicinenews #crispr #RNAengineering #haematopoieticstemcells
